Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 1, 2010, Pages 103-113

  Zafeirakis, Athanasios ^a   Papatheodorou, Georgios ^b   Arhontakis, Athanasios ^a   Gouliamos, Athanasios ^c   Vlahos, Lambros ^c   Limouris, Georgios S ^c  

^a 401 Athens Army Hospital   (Greece)

^b 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

186Re; Bone metastases; Bone pain; Bone turnover markers; Palliative therapies; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; AMINO TERMINAL TYPE I COLLAGEN PROPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TYPE I COLLAGEN PROPEPTIDE; CARBOXY TERMINAL TYPE I COLLAGEN TELOPEPTIDE; ETIDRONIC ACID RE 186; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; PROSPECTIVE STUDY; PROSTATE CARCINOMA; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COLLAGEN TYPE I; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAIN; PALLIATIVE CARE; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 72949121430     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1243-5     Document Type: Article

References (45)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray, et al. 2008 Cancer statistics CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387
2. LE McRea L Karafin 1958 Carcinoma of the prostate: metastases, therapy, and survival - a statistical analysis of 500 cases Int Coll Surg J 29 723 728
3. D Pectasides M Nikolaou D Farmakis I Kanakis A Gaglia P Kountourakis, et al. 2005 Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid Anticancer Res 25 1457 1463 1:CAS:528:DC%2BD2MXkt1Wmsr4%3D 15865105
4. Y Arai H Takeuchi K Oishi O Yoshida 1992 Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20 169 177 10.1002/pros.2990200302 1:CAS:528:DyaK38XmtV2ru70%3D 1374180
5. LM Demers L Costa A Lipton 2000 Biochemical markers and skeletal metastases Cancer 88 2919 2926 10.1002/1097-0142(20000615)88:12+<2919::AID- CNCR7>3.0.CO;2-Z 1:CAS:528:DC%2BD3cXksVCmsL4%3D 10898335
6. J Vinholes R Coleman R Eastell 1996 Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment Cancer Treat Rev 22 289 331 10.1016/S0305-7372(96)90021-3 1:CAS:528:DyaK2sXht12jtbk%3D 9025785 (Pubitemid 27075583)
7. N Koopmans IJ de Jong AJ Breeuwsma E van der Veer 2007 Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach J Urol 178 849 853 10.1016/j.juro.2007.05.029 1:CAS:528:DC%2BD2sXhtValtrbM 17631330 (Pubitemid 47211070)
8. L Costa LM Demers A Gouveia 2000 Correlation of urinary N-telopeptide levels with progression of bone metastases: a prospective study (abstract 12) Cancer 88 Suppl 3094
9. RE Coleman 2002 The clinical use of bone resorption markers in patients with malignant bone disease Cancer 94 2521 2533 10.1002/cncr.10522 12173317 (Pubitemid 34478064)
10. RJ Cook R Coleman J Brown A Lipton P Major YJ Hei, et al. 2006 Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 3361 3367 10.1158/1078-0432.CCR-06-0269 1:CAS:528:DC%2BD28XltFyis78%3D 16740758 (Pubitemid 43910880)
11. CW Ryan D Huo K Bylow LM Demers WM Stadler TO Henderson, et al. 2007 Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid BJU Int 100 1 70 75 10.1111/j.1464-410X.2007.06853.x 1:CAS:528:DC%2BD2sXosVaqu7w%3D 17552955 (Pubitemid 46878544)
12. LM Demers L Costa A Lipton 2003 Biochemical markers and skeletal metastases Clin Orthop 415 S138 S147 10.1097/01.blo0000092979.12414.54 14600604
13. K Jung M Lein C Stephan K Von Hösslin A Semjonow P Sinha, et al. 2004 Comparison of 10 serum bone turnover markers in prostate carcinoma patients with metastatic spread: diagnostic and prognostics implications Int J Cancer 111 783 791 10.1002/ijc.20314 1:CAS:528:DC%2BD2cXmvVenu7s%3D 15252851 (Pubitemid 39062904)
14. JMH de Klerk A van Dijk PP van Rijk BA Zonnenberg AD van het Schip 1991 Pharmacokinetics of rhenium-186 after administration of Re-186-HEDP to patients with bone metastases [abstract] J Nucl Med 32 1082
15. SH Han JM de Klerk S Tan AD van het Schip BH Derksen A van Dijk, et al. 2002 The PLACORHEN study: a double-blind placebo-controlled randomized radionuclide study with 186Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo controlled rhenium study J Nucl Med 43 1150 1156 1:CAS:528:DC%2BD38Xns1elsr0%3D 12215552
16. A Dafermou P Colamussi M Giganti C Cittanti M Bestagno A Piffanelli 2001 A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer Eur J Nucl Med 28 788 798 10.1007/s002590100533 1:CAS:528:DC%2BD3MXkvVWlt7k%3D 11504074 (Pubitemid 32662540)
17. LM Demers 2003 Bone markers in the management of patients with skeletal metastases Cancer 97 3 Suppl 874 879 10.1002/cncr.11127 12548589
18. L Bodei M Lam C Chiesa G Flux B Brans A Chiti, et al. 2008 EANM procedure guideline for treatment of refractory metastatic bone pain Eur J Nucl Med Mol Imaging 35 10 1934 1940 10.1007/s00259-008-0841-y 18649080
19. N Fang Y Li YS Xu D Ma P Fu HQ Gao, et al. 2006 Serum concentrations of IL-2 and TNF-a in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy J Nucl Med 47 242 246 1:CAS:528: DC%2BD28Xhslantr0%3D 16455629
20. MS Soloway SW Hardeman D Hickey J Raymond B Todd B S Soloway, et al. 1988 Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 195 202 10.1002/1097-0142(19880101)61: 1<195::AID-CNCR2820610133>3.0.CO;2-Y 1:STN:280:DyaL1c%2FnvFyltw%3D%3D 3334948
21. Siegel S, Castellan J Jr. Nonparametric statistics for the behavioural sciences. 2nd ed. New York: McGraw Hill; 1988.
22. Motulsky H. Intuitive biostatistics. New York: Oxford University; 1995. p. 113-7.
23. JA Hanley BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 29 36 1:STN:280: DyaL387ltFyksQ%3D%3D 7063747
24. EL Kaplan P Meier 1958 Non-parametric estimation from incomplete observations J Am Stat Accoc 53 457 481 10.2307/2281868
25. FJ Papatheofanis 1997 Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma J Nucl Med 38 1175 1179 1:CAS:528:DyaK2sXls1SmtL4%3D 9255144
26. FJ Papatheofanis 1997 Serum PICP as a bone formation marker in Sr-89 and external beam radiotherapy of prostatic bony metastases Br J Radiol 70 594 598 1:STN:280:DyaK2szntFShtQ%3D%3D 9227252
27. P Guerrieri S Modoni S Parisi V Fusco V Oriolo G Rendina, et al. 1994 Bone formation markers and pain palliation in bone metastases treated with strontium-89 Am J Clin Oncol 17 77 79 10.1097/00000421-199402000-00017 1:STN:280:DyaK2c7ksVGksA%3D%3D 7508680
28. MG Lam A Dahmane WH Stevens PP van Rijk JM de Klerk BA Zonnenberg 2008 Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases Eur J Nucl Med Mol Imaging 35 756 765 10.1007/s00259-007-0659-z 1:CAS:528:DC%2BD1cXjsVCksr4%3D 18157530
29. JS Johansen K Brasso P Iversen B Teisner P Garnero PA Price, et al. 2007 Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival Clin Cancer Res 13 3244 3249 10.1158/1078-0432.CCR-06-2616 1:CAS:528:DC%2BD2sXmtVajurY%3D 17545529 (Pubitemid 46944908)
30. A Lipton R Cook F Saad P Major P Garnero E Terpos, et al. 2008 Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 193 201 10.1002/cncr.23529 1:CAS:528: DC%2BD1cXos1yht7Y%3D 18459173 (Pubitemid 351976401)
31. NB Watts 1999 Clinical utility of biochemical markers of bone remodeling Clin Chem 45 1359 1368 1:CAS:528:DyaK1MXltFGnu74%3D 10430819
32. PJ Hoskin MR Stratford LK Folkes J Regan JR Yarnold 2000 Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity Lancet 355 1428 1429 10.1016/S0140-6736(00)02144-9 1:STN:280:DC%2BD3c3ltVWlug%3D%3D 10791529
33. MD Michaelson RM Marujo MR Smith 2004 Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer Clin Cancer Res 10 8 2705 2708 10.1158/1078-0432.CCR-03-0735 1:CAS:528:DC%2BD2cXjt1CltL0%3D 15102674 (Pubitemid 38509145)
34. M Lein K Miller M Wirth L Weissbach C May K Schmidt, et al. 2009 Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid Prostate 69 6 624 632 10.1002/pros.20917 1:CAS:528:DC%2BD1MXlslCiu7k%3D 19143027
35. S Akimoto Y Furuya K Akakura J Shimazaki H Ito 1999 Inability of bone turnover marker as strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade Prostate 38 28 34 10.1002/(SICI)1097-0045(19990101)38:1<28::AID-PROS3>3.0.CO;2-M 1:STN:280:DyaK1M7jsleqsw%3D%3D 9973106 (Pubitemid 29011014)
36. K Shimozuma H Sonoo M Fukunaga K Ichihara T Aoyama K Tanaka 1999 Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report Jpn J Clin Oncol 29 16 22 10.1093/jjco/29.1.16 1:STN:280:DyaK1M7nt1yjsw%3D%3D 10073146
37. JE Brown RJ Cook P Major A Lipton F Saad M Smith, et al. 2005 Bone markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59 69 1:CAS:528: DC%2BD2MXisVarsA%3D%3D 15632381
38. JM Reynard TJ Peters D Gillatt 1995 Prostate-specific antigen and prognosis in patients with metastatic prostate cancer - a multivariable analysis of prostate cancer mortality Br J Urol 75 507 515 10.1111/j.1464-410X.1995. tb07274.x 1:STN:280:DyaK2MzgvVSisw%3D%3D 7540483
39. JA Smith PH Lange RA Janknegt CC Abbou A deGery 1997 Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate J Urol 157 1329 1334 10.1016/S0022-5347(01) 64963-2 9120932 (Pubitemid 27130808)
40. AW Partin HB Carter DW Chan JI Epstein JE Oesterling RC Rock, et al. 1990 Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 143 747 752 1:STN:280:DyaK3c7ovFegtw%3D%3D 1690309
41. M Koizumi J Yonese I Fukui E Ogata 2002 Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer J Urol 167 1863 1866 10.1016/S0022-5347(05)65250-0 11912449
42. A Jukkola R Tahtela E Tholix K Vuorinen G Blanco L Risteli, et al. 1997 Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP Cancer Res 57 5517 5520 1:CAS:528:DyaK2sXotVGntro%3D 9407961
43. M Santala M Simojoki J Risteli L Risteli A Kauppila 1999 Type I and type III collagen metabolites and peritoneal cells in predicting the clinical outcome of epithelial ovarian cancer patients Clin Cancer Res 5 4091 4096 1:CAS:528:DC%2BD3cXlsV2huw%3D%3D 10632345
44. PN Lara WM Stadler J Longmate DI Quinn J Wexler M Van Loan, et al. 2006 A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res 12 5 1556 1563 10.1158/1078-0432.CCR-05-2074 1:CAS:528:DC%2BD28XitVGms7c%3D 16533781
45. MJ Seibel M Lang WJ Geilenkeuser 2001 Interlaboratory variation of biochemical markers of bone turnover Clin Chem 47 1443 1450 1:CAS:528: DC%2BD3MXls1SqurY%3D 11468235